Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil.

Trial Profile

Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2010

At a glance

  • Drugs PRX 3140 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors EPIX Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 May 2008 Patient numbers amended from 400 to 420 as reported by ClinicalTrials.gov.
    • 21 May 2008 The expected completion date has been identified as Jan 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top